Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 1

3(42.9%)

Phase 2

1(14.3%)

7Total

N/A(3)

Phase 1(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07445217Phase 2Completed

Predictive Validity of the Personal and Social Performance Scale for PANSS Outcomes in Schizophrenia

Role: lead

NCT07351240Not ApplicableActive Not Recruiting

The Acupuncture Treatment Effect in Patients With Schizophrenia

Role: lead

NCT06730178Not ApplicableCompleted

Using Generalized Estimating Equation Analysis in a Study of Relaxation Training in Patients With Insomnia.

Role: lead

NCT04754750Phase 1Completed

Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment

Role: lead

NCT04252131Phase 1Completed

Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia

Role: lead

NCT03730857Phase 1Completed

Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics

Role: lead

NCT03663465Not ApplicableCompleted

The Effect of Hawthorn on Lipoprotein Cholesterol Ratio in Schizophrenics With Antipsychotics

Role: lead

All 7 trials loaded